A major challenge encountered in the rehabilitation of patients with demyelinating disorders is posed by inefficient remyelination. The ability to stimulate Schwann cells (SC) and to augment remyelination would have a great impact the degree of functional recovery in these conditions. The neu gene encodes a tyrosine kinase growth factor receptor, termed p185. Previous studies suggested that p185 plays an important role in SC proliferation and differentiation. Several putative ligands for p185 have been described; two have been molecularly cloned, neu differentiation factor (NDF) and Heregulin. NDF is very similar to or identical to glial growth factor, among the most potent SC mitogens. The training program will provide the candidate with a comprehensive background in neurobiology and immunology through graduate-level coursework. The candidate also will develop expertise in the medical management and neurorehabilitation of patients with central and peripheral demyelinating diseases. The scientific goals are to characterize the expression of p185 ligands in nervous system and to define the biologic function of neu in SC. In Phase I, the developmental expression pattern and cellular specificity of p185 ligands in rat nervous system will be determined. Expression in a several pathological conditions will be characterized, including Wallerian degeneration following experimental allergic encephalomyelitis, peripheral demyelination caused by experimental allergic neuritis, and selected human peripheral nerve conditions associated with SC proliferation. In Phase II, the function of p185 in SC will examined using cultured rat SC, including effects on cell proliferation, morphology, and myelin gene expression. The intermolecular interactions of p185 in the SC membrane will be characterized. These studies will delineate the expression and source of p185 ligands in the nervous systems, begin to define the mechanisms regulating their expression, and clarify their function in SC. These studies should provide valuable insights into potential approaches to enhancing remyelination and thus improving the rehabilitation potential of demyelinating diseases. This program should provide the candidate with a unique combination of expertise in the neurologic, rehabilitative, and scientific aspects of demyelinating diseases.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Physician Scientist Award (K11)
Project #
1K11HD001049-01
Application #
2194597
Study Section
Special Emphasis Panel (SRC (CT))
Project Start
1994-01-01
Project End
1998-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Neurology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Constantinescu, Cris S; Tani, Marie; Ransohoff, Richard M et al. (2005) Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. J Neurochem 95:331-40
Constantinescu, C S; Hilliard, B; Ventura, E et al. (2001) Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively. Clin Immunol 98:23-30
Constantinescu, C S; Lavi, E (2000) Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Curr Eye Res 20:71-6
Constantinescu, C S; Goodman, D B; Hilliard, B et al. (2000) Murine macrophages stimulated with central and peripheral nervous system myelin or purified myelin proteins release inflammatory products. Neurosci Lett 287:171-4
Constantinescu, C S; Hilliard, B; Wysocka, M et al. (1999) IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE). J Neurol Sci 171:60-4
Constantinescu, C S; Wysocka, M; Hilliard, B et al. (1998) Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 161:5097-104
Constantinescu, C S; Goodman, D B; Ventura, E S (1998) Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 62:25-31
Constantinescu, C S; Hilliard, B; Fujioka, T et al. (1998) Pathogenesis of neuroimmunologic diseases. Experimental models. Immunol Res 17:217-27
Constantinescu, C S; Fujioka, T; Kolson, D L et al. (1998) Absence of electromyographically detectable acute neuromuscular transmission defects after intramuscular interferon-gamma administration. J Neurol 245:333-4
Constantinescu, C S; Hilliard, B; Ventura, E et al. (1997) Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 65:190-4

Showing the most recent 10 out of 16 publications